Dupilumab vs conventional AD therapies had less risk for anxiety, depression, and adjustment and sleep disorders, especially among Black patients. Patients with atopic dermatitis (AD) who were ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...